WallStSmart
CTMX

CytomX Therapeutics Inc

NASDAQ: CTMX · HEALTHCARE · BIOTECHNOLOGY

$3.88
-5.66% today

Updated 2026-06-05

Market cap
$653.11M
P/E ratio
P/S ratio
20.15x
EPS (TTM)
$-0.52
Dividend yield
52W range
$2 – $8
Volume
3.9M

CytomX Therapeutics Inc (CTMX) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2013201420152016201720182019202020212022202320242025
Operating cash flow$-8.01M$31.80M$-27.41M$-2.03M$170.37M$-75.52M$-140.48M$5.26M$-119.03M$-110.79M$-56.03M$-86.23M$-75.59M
Capital expenditures$732000.00$1.66M$1.59M$2.18M$1.56M$3.79M$3.50M$2.31M$1.61M$1.74M$840000.00$310000.00$220000.00
Depreciation
Stock-based comp$343000.00$553000.00$3.99M$10.10M$11.29M$16.88M$19.10M$14.79M$13.17M$13.17M$8.56M$7.67M$6.30M
Free cash flow$-8.74M$30.14M$-29.01M$-4.21M$168.81M$-79.31M$-143.98M$2.95M$-120.64M$-112.53M$-56.88M$-86.54M$-75.81M
Investing cash flow
Financing cash flow
Dividends paid$6.71M$0.00$0.00$3.00M
Share repurchases
Debt repayment
Net change in cash$44.82M$72.90M$70.03M$-59.15M$3.43M$13.67M$13.67M

Frequently asked questions

What is CytomX Therapeutics Inc's revenue?

CytomX Therapeutics Inc's trailing twelve-month revenue is $35.54M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is CTMX?

In its most recent fiscal year, CTMX ran a gross margin of 100.00%, an operating margin of -29.35%, and a net margin of -22.79%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does CTMX generate?

CTMX produced $-75.81M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CTMX's balance sheet healthy?

CTMX holds $12.67M in cash and equivalents against — in long-term debt, on $99.01M of shareholder equity. That debt is best read against the cash flow the business throws off each year.